Citius Pharmaceuticals, Inc.
CTXR · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -34.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -7,052.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -6,920.1% |
| EPS Diluted | -0.8 | -1.27 | -1.3 | -1.7 |
| % Growth | 37% | 2.3% | 23.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |